| 複合語 | スコア |
|---|---|
| c difficile infection | 1668.7011331905 |
| c difficile | 1053.2740942931 |
| clostridium difficile | 495.9352868501 |
| clostridium difficile infection | 442.26199319078 |
| difficile infection | 373.01004423393 |
| clostridioides difficile infection | 180.98776763299 |
| c diff | 126.57932561791 |
| recurrent clostridium difficile infection | 122.99769398029 |
| disease control | 121.9645608914 |
| severe disease | 115.90734733279 |
| clin infect dis | 106.69979169497 |
| control hosp epidemiol | 95.318600129888 |
| recurrent c difficile infection | 95.060792560648 |
| community-associated clostridium difficile infection | 86.015848239064 |
| community-associated infection | 81.224213202992 |
| prevention of c difficile infection | 67.246081422256 |
| c difficile spores | 53.930665729841 |
| n engl j med | 51.164929659085 |
| c difficile disease | 50.406580679278 |
| antibiotic use | 49.864248143005 |
| treatment of clostridium | 40.72919202836 |
| antibiotic therapy | 36.569668370283 |
| difficile-associated diarrhea | 33.294331602302 |
| transmission of c difficile | 33.226438558303 |
| j hosp infect | 32.776305508147 |
| strain of clostridium difficile | 32.291389455348 |
| transmission of clostridium difficile | 31.922203509308 |
| epidemiology of clostridium difficile infection | 30.31689537615 |
| recurrent clostridium difficile | 29.836255586252 |
| removal of clostridium difficile spores | 29.783613330887 |
| community-associated c difficile infection | 29.546117462411 |
| incidence of c difficile infection | 29.308718495278 |
| oral vancomycin | 29.132540152015 |
| rates of c difficile infection | 28.502508114285 |
| c difficile incidence | 27.987071318917 |
| c difficile testing | 27.667096440907 |
| spores of c difficile | 26.965332864921 |
| hospitalized patients | 26.25816285832 |
| c difficile colitis | 26.158263565308 |
| epidemic of c difficile infection | 26.136915182273 |
| acquisition of clostridium difficile | 25.90686455606 |
| contamination of c difficile | 25.702931742277 |
| clostridium difficile colitis | 25.131475090736 |
| symptomatic c difficile infection | 24.845224258807 |
| risk factors | 24.640562305928 |
| removal of clostridium difficile | 24.213987361732 |
| toxic megacolon | 24 |
| documented c difficile infection | 23.967656899042 |
| difficile diarrhea | 23.960550990666 |
| difficile infection therapy | 23.745230608439 |
| clostridioides difficile | 22.660490046515 |
| c diff infection | 22.244098523821 |
| burden of clostridium difficile infection | 22.109095385155 |
| emergence of clostridium difficile infection | 22.109095385155 |
| clinical practice guidelines | 21.826996516819 |
| carriage of clostridium difficile | 21.572210301634 |
| clostridium difficile carriage | 21.572210301634 |
| infection control | 21.250815646097 |
| toxin eia | 21.013996367098 |
| antibiotic treatment | 20.172748919954 |
| c diff bacteria | 19.872243752912 |
| united states | 19.798989873223 |
| johnson s | 19.679896712654 |
| disease severity | 19.595917942265 |
| national clostridium difficile standards group | 19.244080291168 |
| difficile colitis | 19.055124848007 |
| community-associated disease | 19.027313840044 |
| fulminant infection | 18.160394801798 |
| initial episode of c difficile infection | 18.117875361631 |
| nosocomial acquisition of clostridium difficile infection | 17.925525811314 |
| c difficile toxin b | 17.781811731186 |
| high rates of c difficile infection | 17.718064012515 |
| prevention of clostridium | 17.124515786414 |
| recurrent clostridium difficile colitis | 17.023867839551 |
| nosocomial clostridium difficile diarrhea | 16.78440638966 |
| human infection | 16.409769129251 |
| rate of c difficile infections | 16.143659726751 |
| severity of clostridium difficile colitis | 16.109147138573 |
| complications of clostridioides difficile infection | 16.085138135166 |
| gerding dn | 15.874507866387 |
| intensive care | 15.79288815543 |
| clindamycin-resistant strain of clostridium difficile | 15.540149991467 |
| infection prevention | 15.026595849101 |
| household transmission of clostridium difficile | 14.645304166986 |
| incident c difficile infections | 14.470235185641 |
| mortality of c difficile infections | 14.470235185641 |
| fulminant clostridium difficile colitis | 14.042110668687 |
| successful treatment | 13.817338054791 |
| symptomatic disease | 13.454342644059 |
| recurrent infection | 13.345872924256 |
| difficile nosocomial transmission | 13.300952651184 |
| use of antibiotics | 13.186983011829 |
| fluoroquinolone use | 12.804343491775 |
| difficile forms | 12.74293000222 |
| potential spread of clostridium difficile | 12.522466841623 |
| nonepidemic clostridium difficile strains | 12.522466841623 |
| use of probiotics | 12.383953976879 |
| current status of clostridium difficile infection epidemiology | 12.249917068431 |
| et al | 12.247448713916 |
| j infect dis | 12.238658339601 |
| limit growth of c difficile | 11.833258156059 |
| healthcare infection control practices advisory committee | 11.790476095554 |
| severe infection | 11.78066232612 |
| prospective clostridium | 11.757504990725 |
| infectious diseases society of america | 11.635364684921 |
| clinical cure rate | 11.616764887363 |
| healthcare epidemiology of america | 11.516298621999 |
| incident episode | 11.420262287518 |
| lancet infect dis | 11.323928312453 |
| asymptomatic patients | 11.253498367851 |
| clinical care | 11.132630734855 |
| recurrent disease | 10.942259198939 |
| limbago b. clostridium difficile | 10.915653306933 |
| high risk | 10.767126541911 |
| miller ma | 10.63659179389 |
| increased risk | 10.360080256445 |
| infectious disease | 10.059467437463 |
| kelly c | 9.9292527589406 |
| hand hygiene | 9.8736245044883 |
| severity of disease | 9.7979589711327 |
| clinical trial | 9.7291971163912 |
| asymptomatic colonization | 9.6711293864119 |
| development of clostridium | 9.350399562456 |
| documented c | 9.2402108647231 |
| initial treatment | 9.2115587031938 |
| adult patients | 9.1884429408264 |
| j antimicrob chemother | 8.9924395582992 |
| difficile-associated disease | 8.8534553576026 |
| antibiotic medicines | 8.6195534967901 |
| cochrane database syst rev | 8.4852813742386 |
| infection prevention measures | 8.4221585055181 |
| perry c | 8.3494730511412 |
| zapka c | 8.3494730511412 |
| pindar c | 8.3494730511412 |
| harmanus c | 8.3494730511412 |
| lyons c | 8.3494730511412 |
| patino c | 8.3494730511412 |
| staley c | 8.3494730511412 |
| care?associated infection | 8.2048845646254 |
| care of patients | 8.0617806492789 |
| case-control study | 7.8719586850617 |
| community-acquired clostridium | 7.8627174732592 |
| intravenous metronidazole | 7.6371896850655 |
| likelihood of infection | 7.6355054442122 |
| nasogastric tube | 7.5446005780976 |
| fulminant disease | 7.4448388728168 |
| fecal microbiota transplantation | 7.377854493525 |
| creatinine level | 7.3256830029694 |
| leukocyte count | 7.200411487357 |
| alcohol-based hand products | 7.1450577591353 |
| controlled trials | 6.9282032302755 |
| superimposed infection | 6.899458017964 |
| infection preventionists | 6.899458017964 |
| refractory infection | 6.899458017964 |
| repeated cases of infection | 6.7569628731473 |
| disease development | 6.7271713220297 |
| outbreak settings | 6.700737917669 |
| antibiotic-associated diarrhea | 6.6874030497642 |
| rectal instillation of vancomycin | 6.6489381094792 |
| terminal disinfection | 6.6400915182019 |
| kundrapu s | 6.6195018392937 |
| judicious antibiotic use | 6.456637412915 |
| recent antibiotic use | 6.456637412915 |
| duration of use | 6.4021717458874 |
| sporicidal agent | 6.3442275806434 |
| wilcox mh | 6.3442275806434 |
| increased incidence | 6.160140576482 |
| ann intern med | 6.1336249480655 |
| updated idsa/shea guidelines | 6.1249938046775 |
| difficile-associated disease surveillance | 6.0523429976916 |
| loo vg | 6 |
| multistep algorithm | 6 |
| pulsed-dose regimen | 6 |
| mcfarland lv | 6 |
| appropriate use | 5.957892135529 |
| routine infection prevention practices | 5.930215283947 |
| mild diarrhea | 5.8856619127654 |
| appropriate management of infection | 5.867080788972 |
| elevated creatinine levels | 5.8083824436817 |
| am j med | 5.7409603581847 |
| controlled study of vinyl glove use | 5.7382461721454 |
| use of gloves | 5.6924250976222 |
| nonsevere disease | 5.6568542494924 |
| proximal disease | 5.6568542494924 |
| clinical resolution of diarrhea | 5.5742555610179 |
| lactate level | 5.5663153674275 |
| brazier j | 5.5044086707916 |
| j clin microbiol | 5.4953326820861 |
| outpatient treatment | 5.4772255750517 |
| treatment of incident | 5.4772255750517 |
| clinical guidelines | 5.446539630663 |
| outbreak setting | 5.4216120216591 |
| additional infection prevention measures | 5.3913348647212 |
| prospective study | 5.318295896945 |
| emergency department | 5.26429605181 |
| infectious disease specialist | 5.2306419440473 |
| infectious disease specialists | 5.2306419440473 |
| toxin testing | 5.1943695600587 |
| instillation of stool | 5.1800401282227 |
| toxigenic culture | 5.1800401282227 |
| underlying disease severity | 5.1395931737013 |
| pattern of disease severity | 5.1395931737013 |
| alcohol-based hand | 5.1307790014945 |
| advanced hiv infection | 5.1253671622755 |
| use of vinyl gloves | 5.0607888021286 |
| gastrointestinal tract | 5.0297337187317 |
| clinical evidence | 5.0297337187317 |
| health care providers | 5.0264737531022 |
| such use | 5.0099701392346 |
| environmental transmission | 5.0099701392346 |
| leischner j | 4.9737947036147 |
| corver j | 4.9737947036147 |
| pepin j | 4.9737947036147 |
| sauk j | 4.9737947036147 |
| hammond j | 4.9737947036147 |
| p?pin j | 4.9737947036147 |
| patient information | 4.8989794855664 |
| hospital outbreak | 4.8205705136679 |
| nelson r. antibiotic treatment | 4.7949934056896 |
| gerber r | 4.7935634538569 |
| clonal multi-institutional outbreak of clostridium | 4.7857818399046 |
| outpatient health care environment | 4.7093283475797 |
| cure rate | 4.6806946386414 |
| risk factor | 4.6806946386414 |
| observational study | 4.6806946386414 |
| 30-day mortality | 4.6806946386414 |
| weiss k | 4.6806946386414 |
| protocol analysis | 4.6806946386414 |
| toxin tests | 4.651161968023 |
| instillation of vancomycin | 4.6057793515969 |
| 147.2 cases | 4.5825756949558 |
| ischemic bowel disease | 4.5788569702133 |
| inflammatory bowel disease | 4.5788569702133 |
| stool tests | 4.5590141139096 |
| asymptomatic carriers | 4.5590141139096 |
| kasper d | 4.5590141139096 |
| patient rooms | 4.5590141139096 |
| modified intention-to-treat analysis | 4.5298688016454 |
| clindamycin use | 4.5270190558379 |
| unnecessary use | 4.5270190558379 |
| short-term use | 4.5270190558379 |
| other diseases | 4.5270190558379 |
| laxative use | 4.5270190558379 |
| nosocomial transmission | 4.5270190558379 |
| community-associated diarrhea | 4.4721359549996 |
| controlled pilot study | 4.4418123097047 |
| terminal cleaning | 4.4267276788013 |
| care of someone | 4.4267276788013 |
| receipt of care | 4.4267276788013 |
| stewardship protocols | 4.4267276788013 |
| immunocompromised persons | 4.4267276788013 |
| family members | 4.4267276788013 |
| resolution of diarrhea | 4.400558683967 |
| open forum infect dis | 4.364985804658 |
| nursing home care | 4.3644945438869 |
| treatment options | 4.3558771746929 |
| severe cases | 4.3467739333546 |
| antibiotic disruption | 4.3097767483951 |
| medical therapy | 4.2813902858562 |
| community-associated cases | 4.2813902858562 |
| transmission of infectious agents | 4.2484406376281 |
| significant reduction | 4.2294850537623 |
| first study | 4.2294850537623 |
| judicious use of antibiotics | 4.2227675591121 |
| prevention measures | 4.2128659306105 |
| cases of contact | 4.2128659306105 |
| other complications | 4.2128659306105 |
| infectious complications | 4.1617914502878 |
| clinical success of metronidazole | 4.1406808334653 |
| donor stool | 4.1195342878142 |
| placebo-controlled trials | 4.1195342878142 |
| dis clin north am | 4.1175193504392 |
| opt-80-004 clinical study group | 4.080093847101 |
| opt-80-003 clinical study group | 4.080093847101 |
| long-term care facility | 4.079297805311 |
| hypervirulent strain | 4.0536004644211 |
| treatment strategies | 4.0536004644211 |
| epidemic strain | 4.0536004644211 |
| noninfectious causes | 4 |
| department of health | 3.9842826037303 |
| transmission of epidemic | 3.9842826037303 |
| person-to-person transmission | 3.9842826037303 |
| other strains | 3.9842826037303 |
| other factors | 3.9842826037303 |
| direct inspection | 3.9359793425309 |
| olson mm | 3.9359793425309 |
| retrospective study | 3.9359793425309 |
| risk increases | 3.9359793425309 |
| antibiotic policy | 3.8943229049609 |
| colonized health care personnel | 3.8511259398089 |
| extended use of metronidazole | 3.7849303181582 |
| known risk factors | 3.7719455481171 |
| established risk factors | 3.7719455481171 |
| hand sanitizer | 3.7511661226171 |
| antibiotic prescription protocol | 3.745284791174 |
| repeated stool testing | 3.7288210710016 |
| advanced age | 3.7224194364084 |
| farm animals | 3.7224194364084 |
| bakken js | 3.7224194364084 |
| lessa fc | 3.7224194364084 |
| flexible sigmoidoscopy | 3.7224194364084 |
| donskey cj | 3.7224194364084 |
| libman md | 3.7224194364084 |
| supplemental intervention | 3.7224194364084 |
| bamberg wm | 3.7224194364084 |
| clabots cr | 3.7224194364084 |
| other bacteria | 3.7077927510673 |
| other tests | 3.7077927510673 |
| other antibiotics | 3.7077927510673 |
| other studies | 3.7077927510673 |
| recent outpatient health care visit | 3.7022878087468 |
| empirical treatment | 3.6628415014847 |
| cdi treatment | 3.6628415014847 |
| aggressive treatment | 3.6628415014847 |
| first recurrent episode | 3.6467519140054 |
| long-term care residents | 3.6342411856643 |
| other laboratory tests | 3.6247148052866 |
| care?associated transmission | 3.6002057436785 |
| potential drug treatment | 3.5953592505049 |
| faecal enema treatment | 3.5953592505049 |
| idsa/shea guidelines | 3.5840246342157 |
| successful use of feedback | 3.578518080138 |
| same episode of diarrhea | 3.578518080138 |
| one study | 3.5565588200778 |
| second study | 3.5565588200778 |
| clinical features | 3.5565588200778 |
| toxin detection | 3.5341188430494 |
| toxin eias | 3.5341188430494 |
| interrupted time-series study | 3.5254687665352 |
| antibiotic stewardship programs | 3.5005501496846 |
| practice improvement | 3.4996355115806 |
| h2-receptor blockers | 3.4641016151377 |
| cornely oa | 3.4641016151377 |
| proton-pump inhibitors | 3.4641016151377 |
| 10-day course | 3.4641016151377 |
| acute care hospitals | 3.4641016151377 |
| systematic review | 3.4641016151377 |
| body fluids | 3.4641016151377 |
| colonization rates | 3.4641016151377 |
| stool transplant | 3.4641016151377 |
| septic shock | 3.4641016151377 |
| stamm we | 3.4641016151377 |
| louie tj | 3.4641016151377 |
| multidrug-resistant organism | 3.4641016151377 |
| mcdonald lc | 3.4641016151377 |
| results of stool studies | 3.4641016151377 |
| fawley wn | 3.4641016151377 |
| fresh stool | 3.4641016151377 |
| suissa s. use | 3.4478752740675 |
| prospective controlled trial | 3.4478752740675 |
| main antibiotic agents | 3.4235051013067 |
| 10-year prospective study | 3.4199518933534 |
| diagnostic tests | 3.4086580994025 |
| clindamycin-resistant strain | 3.4086580994025 |
| virulent strain | 3.4086580994025 |
| strain present | 3.4086580994025 |
| fecal microbiota transplant | 3.3878587775517 |
| clinical success of tolevamer | 3.3604214537127 |
| intestinal microbiota | 3.3503689588345 |
| alcohol-based hand gel | 3.3390829273101 |
| alcohol-based hand sanitizers | 3.3390829273101 |
| difficile-associated colitis | 3.3097509196469 |
| shah s | 3.3097509196469 |
| long-term care facility residents | 3.292905106941 |
| faecal microbiota transplantation | 3.2864605554537 |
| scand j gastroenterol | 3.2706211157025 |
| thorough hand hygiene | 3.2543885763655 |
| strict hand hygiene | 3.2543885763655 |
| effectiveness of hand hygiene | 3.2543885763655 |
| healthcare settings | 3.2531531233956 |
| medical equipment | 3.2531531233956 |
| high leukocyte count | 3.2488866055632 |
| retrospective observational cohort study of patients | 3.2380572012303 |
| fecal contamination | 3.2237097954706 |
| outpatient healthcare settings | 3.2225747786052 |
| gaese c. risk factors | 3.2187078550942 |
| effects of control interventions | 3.2031009475288 |
| many cases | 3.2010858729437 |
| ajr am j roentgenol | 3.2007591148109 |
| toxin production | 3.1934368675747 |
| binary toxin | 3.1934368675747 |
| severe illness | 3.1779718278113 |
| increased leukocyte count | 3.1664800441388 |
| recognized risk factor | 3.14083560495 |
| major risk factor | 3.14083560495 |
| clinical illness ranges | 3.14083560495 |
| overall cure rate | 3.14083560495 |
| stool frequency | 3.1301691601466 |
| duration of therapy | 3.1301691601466 |
| stool consistency | 3.1301691601466 |
| stool softeners | 3.1301691601466 |
| previous hospital | 3.080070288241 |
| different strain | 3.080070288241 |
| concomitant vancomycin | 3.080070288241 |
| immunocompromised patients | 3.0628143136088 |
| fresh fecal microbiota transplantation | 3.0536216384903 |
| new hypervirulent strain | 3.0531455120681 |
| health history | 3.0274001040351 |
| other information | 3.0274001040351 |
| identified health | 3.0274001040351 |
| several factors | 3.0274001040351 |
| health professionals | 3.0274001040351 |
| critical care units | 3.0261714988458 |
| incidence rate ratio | 2.9937951655239 |
| nnesen s | 2.9906975624424 |
| puumala s | 2.9906975624424 |
| weese s | 2.9906975624424 |
| leekha s | 2.9906975624424 |
| infectious causes | 2.9906975624424 |
| fenn s | 2.9906975624424 |
| fowler s | 2.9906975624424 |
| michaud s | 2.9906975624424 |
| fuentes s | 2.9906975624424 |
| dial s | 2.9906975624424 |
| chasan-taber s | 2.9906975624424 |
| sougioultzis s | 2.9906975624424 |
| normal leukocyte count | 2.9595672453546 |
| type of diarrhea | 2.9428309563827 |
| direct contact | 2.9428309563827 |
| persistent diarrhea | 2.9428309563827 |
| recommended practices | 2.9428309563827 |
| standard course | 2.9129506302439 |
| appropriate therapy | 2.9129506302439 |
| colectomy rates | 2.9129506302439 |
| normal creatinine levels | 2.9041912218409 |
| high mortality | 2.8925076085191 |
| oral metronidazole | 2.8925076085191 |
| standard 10-day course | 2.8844991406148 |
| other ggood h bacteria | 2.8647328669885 |
| gj strain h | 2.8536385282275 |
| colonized patients | 2.8502698827718 |
| infected patients | 2.8502698827718 |
| shetty n | 2.8284271247462 |
| stoesser n | 2.8284271247462 |
| dendukuri n | 2.8284271247462 |
| laboratory testing method | 2.8210130123402 |
| such cases | 2.8173132472613 |
| several tests | 2.8173132472613 |
| several studies | 2.8173132472613 |
| efficacy of vinyl gloves | 2.7981664143395 |
| duration of contact precautions | 2.7981664143395 |
| s boulardii fungemia | 2.7981664143395 |
| hospital administrators | 2.7831576837137 |
| hospital epidemiologists | 2.7831576837137 |
| comparison of vancomycin | 2.7831576837137 |
| fulminant colitis | 2.7831576837137 |
| contact precautions | 2.7831576837137 |
| administered vancomycin | 2.7831576837137 |
| poirier a | 2.7831576837137 |
| direct person-to-person contact | 2.7682294565183 |
| disposable medical equipment | 2.766175108537 |
| 10-day course of fidaxomicin | 2.7494592739972 |
| several diagnostic options | 2.736580418555 |
| recurrent symptoms | 2.7355647997348 |
| repeated testing | 2.7355647997348 |
| medical therapies | 2.7355647997348 |
| many commercial toxin eias | 2.7338162726212 |
| jama intern med | 2.7322193018926 |
| updated guidelines | 2.7232698153315 |
| similar severity | 2.7108060108295 |
| imaging tests | 2.7108060108295 |
| hospitalized persons | 2.7108060108295 |
| imaging studies | 2.7108060108295 |
| other opportunistic pathogens | 2.6889452937027 |
| other opportunistic organisms | 2.6889452937027 |
| severe dehydration | 2.6723451177838 |
| tissue culture laboratory | 2.66716827534 |
| prevention web site | 2.66716827534 |
| cessation of diarrhea | 2.6591479484725 |
| epidemics of diarrhea | 2.6591479484725 |
| antibiotic-related diarrhea | 2.6591479484725 |
| drug-associated diarrhea | 2.6591479484725 |
| lactate levels | 2.6591479484725 |
| randomised controlled trial | 2.6366746651365 |
| other physical manipulations | 2.6366746651365 |
| potential source of community acquisition | 2.632148025905 |
| multiple factors | 2.632148025905 |
| controlled interrupted time series | 2.632148025905 |
| glove removal | 2.632148025905 |
| care?associated colonization | 2.632148025905 |
| north america | 2.632148025905 |
| rate of relapse | 2.632148025905 |
| potential source | 2.632148025905 |
| physical examination | 2.632148025905 |
| unstable clinical condition | 2.6153209720237 |
| reported incidence | 2.5900200641113 |
| environmental surfaces | 2.5900200641113 |
| resolution of fever | 2.5900200641113 |
| noninfectious complications of fmt | 2.5873402367724 |
| hospitalised patients | 2.5755095769014 |
| survival of patients | 2.5755095769014 |
| select patients | 2.5755095769014 |
| other tools | 2.5457298950218 |
| other conditions | 2.5457298950218 |
| other circumstances | 2.5457298950218 |
| other mechanisms | 2.5457298950218 |
| other methods | 2.5457298950218 |
| other species | 2.5457298950218 |
| individual cases | 2.5457298950218 |
| flexible tube | 2.5148668593659 |
| nematallah a | 2.5148668593659 |
| pillai a | 2.5148668593659 |
| berstad a | 2.5148668593659 |
| birtles a | 2.5148668593659 |
| gustafsson a | 2.5148668593659 |
| goorhuis a | 2.5148668593659 |
| khoruts a | 2.5148668593659 |
| mutreja a | 2.5148668593659 |
| fang a | 2.5148668593659 |
| anand a | 2.5148668593659 |
| thibault a | 2.5148668593659 |
| recommended duration | 2.5148668593659 |
| phimister a | 2.5148668593659 |
| lewis a | 2.5148668593659 |
| lentnek a | 2.5148668593659 |
| pelletier a | 2.5148668593659 |
| thompson a | 2.5148668593659 |
| webber a | 2.5148668593659 |
| vrieze a | 2.5148668593659 |
| open med | 2.4989993994394 |
| elevated lactate level | 2.4928828716784 |
| large teaching hospital | 2.4928828716784 |
| measurement of serum creatinine | 2.4928828716784 |
| uniforms of hospital workers | 2.4928828716784 |
| appropriate daily environmental cleaning | 2.481963048976 |
| nursing home exposure | 2.4494897427832 |
| virulent strains | 2.4494897427832 |
| likelihood of acquisition | 2.4494897427832 |
| laboratory values | 2.4494897427832 |
| polymer alternative | 2.4494897427832 |
| alternative diagnosis | 2.4494897427832 |
| standard course of fidaxomicin | 2.4494897427832 |
| certain factors | 2.4494897427832 |
| antibiotic-associated pseudomembranous colitis | 2.418271175122 |
| oughton m | 2.3967817269284 |
| nelson r. probiotics | 2.3955779153092 |
| common source | 2.3784142300054 |
| physical findings | 2.3784142300054 |
| similar hospital wards | 2.376176797565 |
| modernising medical microbiology informatics group | 2.3607278634909 |
| gastric acid-suppressive agents | 2.3490100793233 |
| ma ss | 2.3403473193207 |
| idsa/shea guideline | 2.3403473193207 |
| resolution of leukocytosis | 2.3403473193207 |
| diagnostic value | 2.3403473193207 |
| symptom resolution | 2.3403473193207 |
| abdominal imaging | 2.3403473193207 |
| presence of complications | 2.3403473193207 |
| nucleic acid amplification tests | 2.3284355309218 |
| further testing | 2.3003266337912 |
| multiple types of antibiotics | 2.2894284851067 |
| limited studies | 2.2795070569548 |
| certain antibiotics | 2.2795070569548 |
| randomized studies | 2.2795070569548 |
| type of bacteria | 2.2795070569548 |
| o fmalley cm jr | 2.2759701509955 |
| minneapolis va medical center | 2.2564263316234 |
| initial improvement | 2.2360679774998 |
| antegrade vancomycin lavage | 2.2209061548523 |
| abdominal examination findings | 2.2209061548523 |
| case series | 2.2133638394006 |
| fusidic acid | 2.2133638394006 |
| poirier l | 2.2133638394006 |
| enteric pathogen | 2.2133638394006 |
| hardy spores | 2.2133638394006 |
| same effect | 2.2133638394006 |
| nontoxigenic strains | 2.2133638394006 |
| delivery of therapy | 2.2133638394006 |
| evidence of perforation | 2.2133638394006 |
| resistant strains | 2.2133638394006 |
| jones e. bacterial contamination of uniforms | 2.1946410573398 |
| woodhouse k. gastric acid suppression | 2.1946410573398 |
| norin e. faecal | 2.1822472719434 |
| american college of physicians | 2.1822472719434 |
| nathan r | 2.165736770668 |
| marshall r | 2.165736770668 |
| ricciardi r | 2.165736770668 |
| lalancette m | 2.165736770668 |
| periodic guidelines | 2.165736770668 |
| jackson m | 2.165736770668 |
| abd m | 2.165736770668 |
| warny m | 2.165736770668 |
| craig r | 2.165736770668 |
| nieuwdorp m | 2.165736770668 |
| smieja m | 2.165736770668 |
| esposito r | 2.165736770668 |
| alani m | 2.165736770668 |
| bendall r | 2.165736770668 |
| shemko m | 2.165736770668 |
| mccormack r | 2.165736770668 |
| pattani r | 2.165736770668 |
| barnden m | 2.165736770668 |
| killgore g | 2.1406951429281 |
| effects of probiotics | 2.1406951429281 |
| randomized trial | 2.1406951429281 |
| antineoplastic agents | 2.1406951429281 |
| deshpande a. colonization | 2.1398263878673 |
| common enteric pathogen | 2.1398263878673 |
| strains of escherichia coli | 2.1398263878673 |
| urinary tract infections | 2.1398263878673 |
| impact of emergency colectomy | 2.1398263878673 |
| reported efficacy of fmt | 2.1169328630255 |
| various diagnostic assays | 2.1169328630255 |
| solomon k | 2.1147425268811 |
| thorlund k | 2.1147425268811 |
| antibiotic-associated diarrhoea | 2.1147425268811 |
| keel k | 2.1147425268811 |
| savik k | 2.1147425268811 |
| total mortality | 2.1147425268811 |
| tube feeding | 2.1147425268811 |
| oral medication | 2.1147425268811 |
| willard k | 2.1147425268811 |
| crossley k | 2.1147425268811 |
| price k | 2.1147425268811 |
| disposable gloves | 2.1147425268811 |
| american academy of family physicians | 2.1039790110173 |
| macinga d | 2.0597671439071 |
| signs of dehydration | 2.0597671439071 |
| fitts d | 2.0597671439071 |
| number of antibiotics | 2.0597671439071 |
| bakker d | 2.0597671439071 |
| infected persons | 2.0597671439071 |
| drug-resistant bacteria | 2.0597671439071 |
| patient encounter | 2.0597671439071 |
| bad bacteria | 2.0597671439071 |
| narrow-spectrum antibiotics | 2.0597671439071 |
| high-risk persons | 2.0597671439071 |
| antibiotic-resistant bacteria | 2.0597671439071 |
| leopold d | 2.0597671439071 |
| patient populations | 2.0597671439071 |
| patient encounters | 2.0597671439071 |
| lyras d | 2.0597671439071 |
| epidemiologic studies | 2.0597671439071 |
| multinational studies | 2.0597671439071 |
| patient selection | 2.0597671439071 |
| exposure present | 2.0597671439071 |
| roscoe d | 2.0597671439071 |
| national ribotyping-based surveillance scheme | 2.0565711885958 |
| american college of gastroenterology | 2.0396489026555 |
| obvious alternative diagnosis | 2.0396489026555 |
| 1.5 mg/dl | 2 |
| kyne l | 2 |
| ash l | 2 |
| valiquette l | 2 |
| strong evidence | 2 |
| masucci l | 2 |
| kelly cp | 2 |
| mooney l | 2 |
| kelly cr | 2 |
| continued surveillance | 2 |
| multiple recurrences | 2 |
| chiarello l | 2 |
| supporting evidence | 2 |
| cell culture cytotoxicity neutralization assay | 1.9871338585183 |
| u.s. environmental protection agency | 1.9839302766304 |
| lee jt jr | 1.9786024464679 |
| many recommendations | 1.9679896712654 |
| recommended procedure | 1.9679896712654 |
| updated recommendations | 1.9679896712654 |
| many strategies | 1.9679896712654 |
| numerous formulations of probiotics | 1.9559811771959 |
| complete blood count | 1.9559811771959 |
| quality measures | 1.9343364202677 |
| cammarota g | 1.9343364202677 |
| bearman g | 1.9343364202677 |
| chemotherapeutic agents | 1.9343364202677 |
| ianiro g | 1.9343364202677 |
| supportive measures | 1.9343364202677 |
| several naats | 1.9343364202677 |
| alcohol-based handrub | 1.9343364202677 |
| acute-care settings | 1.9343364202677 |
| high morbidity | 1.9343364202677 |
| costamagna g | 1.9343364202677 |
| nonoutbreak settings | 1.9343364202677 |
| several months | 1.9343364202677 |
| antiperistaltic agents | 1.9343364202677 |
| harms of probiotics | 1.9343364202677 |
| dinoi g | 1.9343364202677 |
| relevant measures | 1.9343364202677 |
| cross-over trial | 1.9343364202677 |
| b enzyme immunoassays | 1.9063685859939 |
| new foodborne pathogen | 1.9063685859939 |
| shea long-term-care committee | 1.9063685859939 |
| van dorp sm | 1.9063685859939 |
| alice y. guh | 1.9063685859939 |
| small case series | 1.9063685859939 |
| peritoneal signs | 1.8612097182042 |
| haeck o | 1.8612097182042 |
| intravenous bezlotoxumab | 1.8612097182042 |
| fitzgerald t | 1.8612097182042 |
| brazier js | 1.8612097182042 |
| surawicz cm | 1.8612097182042 |
| schultz me | 1.8612097182042 |
| published trials | 1.8612097182042 |
| steiner t | 1.8612097182042 |
| mulligan me | 1.8612097182042 |
| sitzlar b | 1.8612097182042 |
| disposable gowns | 1.8612097182042 |
| drs. guh | 1.8612097182042 |
| rupp me | 1.8612097182042 |
| toxin-binding polymer | 1.8612097182042 |
| possibility of exposure | 1.8612097182042 |
| current data | 1.8612097182042 |
| concomitant reduction | 1.8612097182042 |
| associated diarrhoea | 1.8612097182042 |
| long-term-care facilities | 1.8612097182042 |
| palda va | 1.8612097182042 |
| delaney ja | 1.8612097182042 |
| guh ay | 1.8612097182042 |
| midtvedt t | 1.8612097182042 |
| delaney cp | 1.8612097182042 |
| signs of peritonitis | 1.8612097182042 |
| potential benefits | 1.8612097182042 |
| lesur o | 1.8612097182042 |
| golubchik t | 1.8612097182042 |
| respiratory infections | 1.8612097182042 |
| management changes | 1.8612097182042 |
| appropriate implementation | 1.8612097182042 |
| baker me | 1.8612097182042 |
| subtotal colectomy | 1.8612097182042 |
| alary me | 1.8612097182042 |
| intravenous immunoglobulins | 1.8612097182042 |
| ann surg | 1.8612097182042 |
| saccharomyces boulardii | 1.8612097182042 |
| same room | 1.8612097182042 |
| birch t | 1.8612097182042 |
| domestic animals | 1.8612097182042 |
| national action plan | 1.8493111942973 |
| van nood e | 1.8171205928321 |
| preeta k. kutty | 1.8171205928321 |
| protective effect of gowns | 1.8171205928321 |
| supplemental enteral feedings | 1.7817974362807 |
| specific immune defects | 1.7817974362807 |
| human monoclonal antibody | 1.7817974362807 |
| current state of knowledge | 1.7817974362807 |
| high-level fluoroquinolone resistance | 1.7817974362807 |
| abdominal distention | 1.7782794100389 |
| lack of improvement | 1.7782794100389 |
| compared fmt | 1.7782794100389 |
| dunn jr | 1.7782794100389 |
| farley mm | 1.7782794100389 |
| sporicidal disinfectant | 1.7782794100389 |
| abdominal pain | 1.7782794100389 |
| significant decrease | 1.7782794100389 |
| anderson jr | 1.7782794100389 |
| gastrointestinal manipulation | 1.7782794100389 |
| gastrointestinal cancer | 1.7782794100389 |
| significant ileus | 1.7782794100389 |
| expected improvement | 1.7782794100389 |
| riggs mm | 1.7782794100389 |
| recommended dosage | 1.7782794100389 |
| autologous fmt | 1.7782794100389 |
| samore mh | 1.7782794100389 |
| duodenal infusion of donor feces | 1.7692284081335 |
| limit of detection | 1.7320508075689 |
| smith mb | 1.7320508075689 |
| limited data | 1.7320508075689 |
| microbial disruption | 1.7320508075689 |
| primary method | 1.7320508075689 |
| colonic perforation | 1.7320508075689 |
| persistent fever | 1.7320508075689 |
| healthy donors | 1.7320508075689 |
| polymerase chain reaction | 1.6983813295649 |
| alcohol fs ability | 1.6983813295649 |
| positive predictive values | 1.6983813295649 |
| toxin-binding anion-exchange resins | 1.6983813295649 |
| enzyme-linked immunosorbent assays | 1.6983813295649 |
| specific classes | 1.6817928305074 |
| mu y | 1.6817928305074 |
| prior recurrences | 1.6817928305074 |
| muganda cp | 1.6817928305074 |
| gordon sm | 1.6817928305074 |
| summers km | 1.6817928305074 |
| moorthi km | 1.6817928305074 |
| significance of findings | 1.6817928305074 |
| golan y | 1.6817928305074 |
| notermans dw | 1.6817928305074 |
| gill ja | 1.6817928305074 |
| coen p | 1.6817928305074 |
| clostridial diarrhoea | 1.6817928305074 |
| nursing homes | 1.6817928305074 |
| reusable equipment | 1.6817928305074 |
| watery stools | 1.6817928305074 |
| loose stools | 1.6817928305074 |
| unformed stools | 1.6817928305074 |
| vos wm | 1.6817928305074 |
| specific syndromes | 1.6817928305074 |
| negative results | 1.6817928305074 |
| holzbauer sm | 1.6817928305074 |
| shanholtzer cj | 1.6817928305074 |
| crook dw | 1.6817928305074 |
| isolation precautions | 1.6817928305074 |
| carter y | 1.6817928305074 |
| tenover fc | 1.6817928305074 |
| eyre dw | 1.6817928305074 |
| common cause | 1.6817928305074 |
| subsequent recurrences | 1.6817928305074 |
| concurrent diagnosis | 1.6817928305074 |
| brassard p | 1.6817928305074 |
| villemure p | 1.6817928305074 |
| hanrahan ja | 1.6817928305074 |
| normal saline | 1.6817928305074 |
| mullane km | 1.6817928305074 |
| first recurrence | 1.6817928305074 |
| weiler md | 1.6817928305074 |
| therapeutic options | 1.6817928305074 |
| prevalence of pcr ribotypes | 1.5874010519682 |
| yellow mucosal plaques | 1.5874010519682 |
| aliment pharmacol ther | 1.5874010519682 |
| whole genome sequencing | 1.5874010519682 |
| modify ii investigators | 1.5874010519682 |
| margaret trexler hessen | 1.5874010519682 |
| mobile genetic elements | 1.5874010519682 |
| moderate adverse events | 1.5874010519682 |
| short-chain fatty acids | 1.5874010519682 |
| killgore ge | 1.5650845800733 |
| johal ss | 1.5650845800733 |
| less-invasive procedure | 1.5650845800733 |
| minimum criteria | 1.5650845800733 |
| microbial balance | 1.5650845800733 |
| healthy person | 1.5650845800733 |
| songer jg | 1.5650845800733 |
| cadnum jl | 1.5650845800733 |
| oughton mt | 1.5650845800733 |
| generalized debility | 1.5650845800733 |
| high-risk drugs | 1.5650845800733 |
| acidic environment | 1.5650845800733 |
| colonic abnormalities | 1.5650845800733 |
| gould lh | 1.5650845800733 |
| general debility | 1.5650845800733 |
| huber ra | 1.5650845800733 |
| lee ch | 1.5650845800733 |
| simor ae | 1.5650845800733 |
| smith z | 1.5650845800733 |
| glatt ae | 1.5650845800733 |
| unrelated donors | 1.5650845800733 |
| primary means | 1.5650845800733 |
| four hospitals | 1.5650845800733 |
| frozen inoculum | 1.5650845800733 |
| bartlett jg | 1.5650845800733 |
| private room | 1.5650845800733 |
| alcohol rub | 1.5650845800733 |
| prespecified criteria | 1.5650845800733 |
| rhinehart e | 1.5650845800733 |
| frozen vs | 1.5650845800733 |
| shah ps | 1.5650845800733 |
| saxton jd | 1.5650845800733 |
| previous version | 1.5650845800733 |
| high-touch surfaces | 1.5650845800733 |
| arch surg | 1.5650845800733 |
| siegel jd | 1.5650845800733 |
| kaplan jl | 1.5650845800733 |
| gould cv | 1.5650845800733 |
| antineoplastic chemotherapy | 1.5650845800733 |
| associated deaths | 1.5650845800733 |
| dunstan f | 1.5650845800733 |
| leukemoid reaction | 1.5650845800733 |
| lamontagne f | 1.5650845800733 |
| hughes ra | 1.5650845800733 |
| acute abdomen | 1.5650845800733 |
| domestic pets | 1.5650845800733 |
| davis mb | 1.5650845800733 |
| intestinal obstruction | 1.5650845800733 |
| exception of cytomegalovirus | 1.4142135623731 |
| jabbar u | 1.4142135623731 |
| bradley sf | 1.4142135623731 |
| knetsch cw | 1.4142135623731 |
| sadowsky mj | 1.4142135623731 |
| early surgery | 1.4142135623731 |
| chitnis as | 1.4142135623731 |
| fourth-generation cephalosporins | 1.4142135623731 |
| madoff rd | 1.4142135623731 |
| bakkanagari sr | 1.4142135623731 |
| independent predictor | 1.4142135623731 |
| mahida yr | 1.4142135623731 |
| colon preparation | 1.4142135623731 |
| careful adherence | 1.4142135623731 |
| browne hp | 1.4142135623731 |
| antiseptic wipes | 1.4142135623731 |
| vandvik po | 1.4142135623731 |
| winston lg | 1.4142135623731 |
| surgical consultation | 1.4142135623731 |
| wilson rg | 1.4142135623731 |
| retail meats | 1.4142135623731 |
| adequate distribution | 1.4142135623731 |
| sethi ak | 1.4142135623731 |
| pig farms | 1.4142135623731 |
| white house | 1.4142135623731 |
| euro surveill | 1.4142135623731 |
| corless jk | 1.4142135623731 |
| mayo clinic | 1.4142135623731 |
| zoetendal eg | 1.4142135623731 |
| short term | 1.4142135623731 |
| iwen pc | 1.4142135623731 |
| asked questions | 1.4142135623731 |
| passive immunotherapy | 1.4142135623731 |
| quan tp | 1.4142135623731 |
| baxter nn | 1.4142135623731 |
| martzen mr | 1.4142135623731 |
| possible sepsis | 1.4142135623731 |
| eckstein ec | 1.4142135623731 |
| end-organ dysfunction | 1.4142135623731 |
| geriatric service | 1.4142135623731 |
| fecal?oral route | 1.4142135623731 |
| debast sb | 1.4142135623731 |
| renal failure | 1.4142135623731 |
| parada jp | 1.4142135623731 |
| post kw | 1.4142135623731 |
| apparent response | 1.4142135623731 |
| goldenberg jz | 1.4142135623731 |
| rothenberger da | 1.4142135623731 |
| bulens sn | 1.4142135623731 |
| nicolle le | 1.4142135623731 |
| acceptable size | 1.4142135623731 |
| special diet | 1.4142135623731 |
| loop ileostomy | 1.4142135623731 |
| strausbaugh lj | 1.4142135623731 |
| single test | 1.4142135623731 |
| zabarsky tf | 1.4142135623731 |
| zar fa | 1.4142135623731 |
| dumyati gk | 1.4142135623731 |
| nonrandomized reports | 1.4142135623731 |
| petrof eo | 1.4142135623731 |
| bliss dz | 1.4142135623731 |
| past outbreaks | 1.4142135623731 |
| dingle ke | 1.4142135623731 |
| research purposes | 1.4142135623731 |
| brownstein re | 1.4142135623731 |
| gut lumen | 1.4142135623731 |
| sanders im | 1.4142135623731 |
| ten years | 1.4142135623731 |
| connor tr | 1.4142135623731 |
| nonpathogenic yeasts | 1.4142135623731 |
| cooper bs | 1.4142135623731 |
| kwok ry | 1.4142135623731 |
| jury la | 1.4142135623731 |
| james pd | 1.4142135623731 |
| available laboratories | 1.4142135623731 |
| important contributor | 1.4142135623731 |
| morgan dj | 1.4142135623731 |
| coffin se | 1.4142135623731 |
| length of stay | 1.4142135623731 |
| irreversible neurotoxicity | 1.4142135623731 |
| absence of laxatives | 1.4142135623731 |
| gessert ce | 1.4142135623731 |
| carroll kc | 1.4142135623731 |
| farrow ka | 1.4142135623731 |
| beldavs zg | 1.4142135623731 |
| naat confirmation | 1.4142135623731 |
| peripartum women | 1.4142135623731 |
| 4-log reductions | 1.4142135623731 |
| glutamate dehydrogenase | 1.4142135623731 |
| didelot x | 1.4142135623731 |
| molecular typing | 1.4142135623731 |
| jump rl | 1.4142135623731 |
| belflower rm | 1.4142135623731 |
| tool kit | 1.4142135623731 |
| adkins sh | 1.4142135623731 |
| few days | 1.4142135623731 |
| pretest probability | 1.4142135623731 |
| electrolyte imbalances | 1.4142135623731 |
| banach db | 1.4142135623731 |
| hwang sw | 1.4142135623731 |
| conventional handwashing | 1.4142135623731 |
| poxton ir | 1.4142135623731 |
| li q | 1.4142135623731 |
| tedesco fj | 1.4142135623731 |
| edmonds sl | 1.4142135623731 |
| obuchowski na | 1.4142135623731 |
| gordin fm | 1.4142135623731 |
| organic matter | 1.4142135623731 |
| expert panel | 1.4142135623731 |
| poor outcome | 1.4142135623731 |
| somero ms | 1.4142135623731 |
| professional organizations | 1.4142135623731 |
| region of quebec | 1.4142135623731 |
| sambol sp | 1.4142135623731 |
| 51.9 episodes | 1 |
| .0 mg/dl | 1 |
American College of Physicians, Japan Chapter Cummunication Server